Adaptive Biotechnologies Corporation Common Stock (ADPT)
Adaptive Biotechnologies Corporation focuses on immune-driven medicine and develops immune system-based diagnostics and therapeutics. It leverages its proprietary immune sequencing platform to understand and interpret the adaptive immune system, primarily through analyzing T-cell and B-cell receptors to improve disease detection and treatment. The company collaborates with various research and pharmaceutical organizations to advance immunotherapy and immune-based diagnostics.
Company News
Adaptive Biotechnologies reported strong Q2 2025 results with 36% revenue growth, primarily driven by minimal residual disease (MRD) business. The company beat analyst expectations and raised its MRD revenue guidance for 2025.
The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.
